Search

Introduction: Diabetes treatment requires the involvement of people with diabetes in the form of regular exercise and lifestyle measures. Exercise is an important strategy in the management of diabetes. Regular exercise is necessary for good Glycaemic control and Metabolic health. Newer methods like WhatsApp-based communication are now finding their way into diabetes care. It can assist to maintain a regular exercise program and reduce blood sugar levels. Materials and Methods: A total of 262 patients were selected by random sampling. They were of age 15-65 years with DM. Inclusion Criteria: 1. Known case of DM 2. Consent to share data. 3. Ability to use WhatsApp. Exclusion criteria: 1. Inability to use WhatsApp 2. Any condition which impairs movement. Randomly allocated to two groups of 131 persons. The first group participants were added to a WhatsApp group and asked to send their exercise and blood glucose data to the clinic over WhatsApp. The other group was treated as usual. Participants were monitored for HBA1C at 3 and 6 months and surveyed for exercise patterns by a questionnaire at 3 and 6 months. The results were analyzed using SPSS. Result: After excluding, 2 dropped patients from both groups remaining 258 patient data shows: HBA1C reduction in the WhatsApp group of 1.9% as compared to 1% in the routine care group. The number of patients achieving the target goal of 7% HBA1C in the WhatsApp group (74%) as compared to the routine group (56%) . 77% of patients in the WhatsApp group did regular exercise as compared to 42% in the routine group. Discussion: With newer modalities, the ways and means to communicate with patients have improved. This has paved way for newer messaging platforms like WhatsApp for better patient-centric communication. These tools if used correctly can reduce in-person follow-ups but increase the connection between caregiver and patients and can result in better patient outcomes and will lead to reduced complications and financial implications. Disclosure B.Saboo: None. A.Shrivastava: None. A.Tewari: None. A.V.Inamdar: None. S.Saboo: None. B.D.Saboo: None.

Introduction: As per the recent International Diabetes Federation (IDF) atlas, there are 537million adults living with diabetes. Indians with the same body mass index (BMI) have higher central adiposity and insulin resistance compared to Caucasians. High insulin resistance in people with diabetes predisposes them to Nonalcoholic Fatty Liver Disease (NAFLD) . TG/HDL ratio is emerging as a sensitive marker of insulin resistance. Liver stiffness measurements predict advanced fibrosis in people with diabetes. The current study aims to correlate TG/HDL ratio and liver stiffness measurements using fibro scans in people with diabetes. Material and Methods: A total of 181 people with diabetes coming for the first time at our center underwent liver stiffness measurements using fibro scans after taking consent, people on prior lipid-lowering therapy and thiazolidinedione therapy were excluded from the study. Results: Median stiffness ranged from 2.3kpa to 34.8kpa (median of 8.0kpa) , TG/ HDL ratio values ranged from 0.5-29.3 (median of 4.5) . Median stiffness, correlated with TG/HDL ratio correlation coefficient, was 0.2 (p 0.01) . Further 26.5% subjects had advanced fibrosis (Liver stiffness measurement (LSM) >9.1) , 23.7% of male subjects and 30% of female subjects had advanced fibrosis. Males and females with LSM >9.1 had high TG/ HDL ratio, mean 4.9 in males (range 2.5-13.7) and 4.9 in females (range 1.0-17) . These values were much higher than TG/HDL values of 0.9 and 1.2 used in females and males respectively, as cutoffs to predict insulin resistance. Discussion: Previous studies have correlated TG/HDL ratio with NAFLD in nondiabetic individuals using ultrasonography. Fibro scan is a more sensitive and specific modality to screen for NAFLD. Median stiffness predicts liver fibrosis. There is a high incidence of advanced fibrosis in the index study, which correlated with TG/HDL ratio. All male and female subjects with advanced fibrosis had a high TG/HDL ratio. Disclosure A.Tewari: None. R.Choudhury: None. V.Tewari: None. J.Tewari: None. B.Saboo: None. A.Shrivastava: None. S.S.Dariya: None. V.Chavda: None. D.Hasnani: None. A.V.Inamdar: None.

Introduction: Erectile dysfunction (ED) is an important complication of diabetes which is under-reported with well known association with CAD. ED is also considered as one of the earliest markers of endothelial dysfunction. Material and Method: 458 sexually active males of age >18 Years, with diabetes were enrolled. The English and Hindi (regional language) translated version of The International Index of Erectile Function (IIEF) Questionnaire was used. Subjects were to respond to IIEF based on their subjective feeling related to ED, Orgasmic function, Sexual desire, Intercourse satisfaction and overall satisfaction in past 4 weeks. Study was conducted from August 2018 to April 2019 at 11 centers of a large metropolitan city, Lucknow in North India after ethics committee approval. Result: Mean age of the patients was 47.64 years (±9.59), weight 74.6 Kg (± 13.2) BMI 26.8 Kg/M2 (±3.97) and abdominal circumference 97.06cm (±10.79). The prevalence of ED and Orgasmic function defect (OFD) was found to be 32% and 43.8% respectively.27.8% had both and 48.4% either ED or OFD. ED was found to be significantly associated with age (p=0.0006), duration of diabetes (p=0.0101), age of onset of diabetes (p=0.0096), macrovascular complications (p=0.0032), serum creatinine (p=0.0141) and use of beta blocker (p=0.032). ED was not significantly associated with hypertension (p=0.091), hypoglycaemia (p=0.2066), HbA1c (p=0.305), statin (p=0.2044), mean platelet volume (p=0.5822) and microvascular complications of diabetes (p=0.0865). Conclusion: ED was present in nearly one third subjects with diabetes. Nearly half subjects have ED/OFD. Patients with longer duration of diabetes, higher age and with macrovascular complications should proactively be asked about their sexual function and an objective assessment should be done with IIEF questionnaire to unearth this complication. These subjects should be considered for other macrovascular complication screening. Disclosure M. Gupta: None. K. Chandra: None. A. Pande: None. R. Awasthi: None. A. Tewari: None. V. Agarwal: None. D. Kumar: None. N.R. Gupta: None. S.K. Chaubey: None. S. Chowdhary: None. M.S. Ansari: None.